These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 3927481

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

  • 3. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Dec 06; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A, Bonaiuto M, Lanzafame F, Mileto A, Pernice F, Cinquegrani M, Mazza G, Micali G, Pangallo A, Fodale P.
    Clin Ter; 1988 Mar 15; 124(5):373-81. PubMed ID: 2974348
    [No Abstract] [Full Text] [Related]

  • 5. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
    Goldberg AC, Schonfeld G, Feldman EB, Ginsberg HN, Hunninghake DB, Insull W, Knopp RH, Kwiterovich PO, Mellies MJ, Pickering J.
    Clin Ther; 1989 Mar 15; 11(1):69-83. PubMed ID: 2655907
    [Abstract] [Full Text] [Related]

  • 6. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L, Németh Csóka M, Szám I, Pados G, Karádi I, Köszegi G, Kusztos R.
    Orv Hetil; 1986 Oct 05; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Oct 05; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P, Hausmann L, Goebel KM.
    Artery; 1980 Oct 05; 8(6):537-46. PubMed ID: 6114725
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate.
    Becker M, Staab D, Von Bergman K.
    Pediatrics; 1992 Jan 05; 89(1):138-42. PubMed ID: 1727999
    [Abstract] [Full Text] [Related]

  • 11. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K, Krempler F, Schellenberg B, Schlierf G.
    Acta Med Austriaca; 1979 Jan 05; 6(3):90-4. PubMed ID: 547652
    [Abstract] [Full Text] [Related]

  • 12. Clinical experience with bezafibrate.
    Schubotz R, Schneider J, Hausmann L, Mühlfellner G, Mühlfellner O, Kaffarnik H.
    Artery; 1980 Jan 05; 8(6):553-9. PubMed ID: 7259534
    [Abstract] [Full Text] [Related]

  • 13. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
    Bradford RH, Goldberg AC, Schonfeld G, Knopp RH.
    Atherosclerosis; 1992 Jan 05; 92(1):31-40. PubMed ID: 1575820
    [Abstract] [Full Text] [Related]

  • 14. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR.
    QJM; 1995 Jun 05; 88(6):421-7. PubMed ID: 7648234
    [Abstract] [Full Text] [Related]

  • 15. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Jun 05; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 16. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I, Naumova R, Kerekovska M, Balabanski L.
    Vutr Boles; 1987 Jun 05; 26(1):96-101. PubMed ID: 3590738
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR, Klemens UH, Vollmar LJ, Lang PD.
    Med Klin; 1978 Dec 08; 73(49):1731-7. PubMed ID: 723760
    [Abstract] [Full Text] [Related]

  • 18. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P, Weisweiler P.
    Artery; 1980 Dec 08; 7(6):464-70. PubMed ID: 7236016
    [Abstract] [Full Text] [Related]

  • 19. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A, Ljachnicky N.
    Schweiz Rundsch Med Prax; 1988 Jul 05; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.